Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Autism Res ; 12(7): 1087-1100, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31025834

RESUMO

Compelling evidence for the far-reaching role of oxytocin (OT) in social cognition and affiliative behaviors set the basis for examining the association between genetic variation in the OT receptor (OXTR) gene and risk for autism spectrum disorder (ASD). In the current study, gene-environment interaction between OXTR and prenatal exposure to either OT or OXTR antagonist (OXTRA) in predicting early social communication development was examined. One hundred and fifty-three children (age: M = 4.32, SD = 1.07) were assigned to four groups based on prenatal history: children whose mothers prenatally received OXTRA and Nifedipine to delay preterm labor (n = 27); children whose mothers received Nifedipine only to delay preterm labor (n = 35); children whose mothers received OT for labor augmentation (n = 56), and a no intervention group (n = 35). Participants completed a developmental assessment of intelligence quotient (IQ), adaptive behavior, and social communication abilities. DNA was extracted via buccal swab. A genetic risk score was calculated based on four OXTR single nucleotide polymorphisms (rs53576, rs237887, rs1042778, and rs2254298) previously reported to be associated with ASD symptomatology. OXTRrisk-allele dosage was associated with more severe autism diagnostics observation schedule (ADOS) scores only in the OXTRA group. In contrast, in the Nifedipine, OT, and no intervention groups, OXTRrisk-allele dosage was not associated with children's ADOS scores. These findings highlight the importance of both genetic and environmental pathways of OT in signaling early social development and raise the need for further research in this field. Autism Res 2019, 12: 1087-1100. © 2019 International Society for Autism Research, Wiley Periodicals, Inc. LAY SUMMARY: In the current study, we examined if the association between prenatal exposure to an oxytocin receptor antagonist (OXTRA) and autism spectrum disorder (ASD) related impairments are dependent on an individual's genetic background for the oxytocin receptor gene (OXTR). Children who carried a greater number of risk alleles for the OXTR gene and whose mothers received OXTRA to delay preterm labor showed more ASD-related impairments. The results highlight the importance of both genetic and environmental pathways of oxytocin in shaping early social development.


Assuntos
Transtorno do Espectro Autista/induzido quimicamente , Transtorno do Espectro Autista/genética , Nifedipino/efeitos adversos , Nifedipino/uso terapêutico , Efeitos Tardios da Exposição Pré-Natal/genética , Receptores de Ocitocina/antagonistas & inibidores , Receptores de Ocitocina/genética , Adulto , Criança , Pré-Escolar , Transtornos da Comunicação/induzido quimicamente , Transtornos da Comunicação/genética , Quimioterapia Combinada , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Trabalho de Parto Prematuro/tratamento farmacológico , Ocitocina/efeitos adversos , Ocitocina/uso terapêutico , Gravidez , Medição de Risco , Mudança Social , Transtorno de Comunicação Social/induzido quimicamente , Transtorno de Comunicação Social/genética , Tocolíticos/efeitos adversos , Tocolíticos/uso terapêutico
2.
JAMA Netw Open ; 2(4): e191435, 2019 04 05.
Artigo em Inglês | MEDLINE | ID: mdl-30951155

RESUMO

Importance: The reproductive safety of benzodiazepine/z-hypnotic exposure on child longer-term developmental risks remains unresolved. Objective: To quantify the association of motor, communication, and attention-deficit/hyperactivity disorder (ADHD) symptoms in preschoolers with gestational benzodiazepine/z-hypnotic exposure by timing and duration and coexposure to opioids or antidepressants. Design, Setting, and Participants: Nationwide, population-based Norwegian Mother and Child Cohort Study, recruiting pregnant women from 1999 to 2008, with child follow-up from ages 6, 18, and 36 months to ages 5, 7, and 8 years. Follow-up of teenagers is ongoing. The study included women with depressive/anxiety (n = 4195), sleeping (n = 5260), or pain-related (n = 26 631) disorders before and/or during pregnancy. Exposures: For the timing analyses, children exposed to benzodiazepines/z-hypnotics in midpregnancy (weeks 17-28) or late pregnancy (week 29 or later) vs those born to nonmedicated women. For the duration and coexposure analyses, benzodiazepine/z-hypnotic treatment for multiple 4-week intervals vs 1 and co-use of benzodiazepine/z-hypnotic with opioids or antidepressants vs sole benzodiazepine/z-hypnotic use. Main Outcomes and Measures: Parent-reported motor and communication skills (Ages and Stages Questionnaires) and ADHD symptoms (Conners' Parent Rating Scale-Revised) at child median age of 5.1 years (interquartile range, 5.0-5.3 years) as standardized mean scores. General linear propensity score-adjusted and marginal structural models were fitted. Analyses were stratified by maternal disorder. Results: Of 41 146 eligible pregnancy-child dyads, 36 086 children (18 330 boys and 17 756 girls) were included, of whom 283 (0.8%) were prenatally exposed to benzodiazepines/z-hypnotics (134 in the depressive/anxiety, 60 in the sleeping, and 89 in the pain-related disorders). There was no increased risk for greater ADHD symptoms or fine motor deficits after intrauterine benzodiazepine/z-hypnotic exposure at different time points. Children born to women with depressive/anxiety disorders who took benzodiazepines/z-hypnotics in late pregnancy had greater gross motor (weighted ß, 0.67; 95% CI, 0.21-1.13) and communication (weighted ß, 0.35; 95% CI, 0.04-0.65) deficits than unexposed children. There was no evidence for substantial duration or coexposure associations. Conclusions and Relevance: These findings suggest no substantial detrimental risk on child fine motor and ADHD symptoms after prenatal benzodiazepine/z-hypnotic exposure alone or in combination with opioids or antidepressants. Residual confounding by indication and/or a higher drug dose regimen among women with anxiety/depression may explain the moderate association of gross motor and communication deficits with late-pregnancy benzodiazepine/z-hypnotic use.


Assuntos
Transtorno do Deficit de Atenção com Hiperatividade/diagnóstico , Benzodiazepinas/efeitos adversos , Hipnóticos e Sedativos/efeitos adversos , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Ansiedade/tratamento farmacológico , Transtorno do Deficit de Atenção com Hiperatividade/epidemiologia , Transtorno do Deficit de Atenção com Hiperatividade/etiologia , Benzodiazepinas/uso terapêutico , Criança , Pré-Escolar , Estudos de Coortes , Transtornos da Comunicação/induzido quimicamente , Transtornos da Comunicação/epidemiologia , Depressão/tratamento farmacológico , Feminino , Idade Gestacional , Humanos , Hipnóticos e Sedativos/uso terapêutico , Lactente , Masculino , Transtornos Motores/induzido quimicamente , Transtornos Motores/epidemiologia , Noruega/epidemiologia , Medidas de Resultados Relatados pelo Paciente , Gravidez
3.
Semin Speech Lang ; 25(4): 309-21, 2004 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-15599821

RESUMO

In this article we will review available evidence concerning the effects of forebrain catecholaminergic and cholinergic activity on verbal perseveration. The anatomy and physiology of these two major neuropharmacological systems make it likely that they influence speech and language functioning directly as well as the cognitive systems that have an indirect impact on speech and language functions. Both catecholaminergic and cholinergic agents have been shown to influence executive cognitive functions (ECFs) such as "resistance to interference" and "attentional switching" as well as mnemonic encoding and retrieval processes. The ECF effects are most likely mediated by prefrontal cortex; mnemonic processes are mediated by both prefrontal and temporal lobes. Although no full-scale clinical trials on the effects of pharmacological agents on verbal perseveration have been conducted as yet, existing preclinical trials suggest that both presynaptic and postsynaptic dopaminergic agents can reduce perseverative responding by increasing inhibitory control processes. Cholinesterase inhibitors and other cholinergic agents can reduce perseverative responding by reducing verbal intrusions.


Assuntos
Catecolaminas/farmacologia , Colinérgicos/farmacologia , Transtornos da Comunicação/induzido quimicamente , Inibidores da Captação de Neurotransmissores/farmacologia , Prosencéfalo/efeitos dos fármacos , Distúrbios da Fala/induzido quimicamente , Acetilcolina/farmacologia , Agonistas alfa-Adrenérgicos/efeitos adversos , Agonistas alfa-Adrenérgicos/farmacologia , Catecolaminas/efeitos adversos , Colinérgicos/efeitos adversos , Transtornos da Comunicação/fisiopatologia , Dopamina/farmacologia , Humanos , Inibidores da Captação de Neurotransmissores/efeitos adversos , Norepinefrina/farmacologia , Córtex Pré-Frontal/efeitos dos fármacos , Córtex Pré-Frontal/fisiologia , Prosencéfalo/fisiologia , Distúrbios da Fala/fisiopatologia , Lobo Temporal/efeitos dos fármacos , Lobo Temporal/fisiologia , Comportamento Verbal/efeitos dos fármacos , Comportamento Verbal/fisiologia
4.
Disabil Rehabil ; 25(20): 1158-67, 2003 Oct 21.
Artigo em Inglês | MEDLINE | ID: mdl-14534059

RESUMO

PURPOSE: In 1981, a progressive multi-systemic disease called Toxic Oil Syndrome (TOS) appeared in Spain as an epidemic that affected 20,000 people. The International Classification of Impairments, Disabilities and Handicaps (ICIDH) was chosen to characterize the health status of patients more severely affected by TOS. METHODS: A random sample of 292 with permanent disability was selected. Disability was assessed with a questionnaire based on ICIDH and the Stanford Health Assessment Questionnaire. Handicap was measured using London Handicap Scale. Distributions of the proportions and 95% confidence intervals for disabilities, handicaps were calculated and stratified by dimensions, age and sex. The chi2 test was used for inter-group comparisons. RESULTS: Two hundred and fourteen patients were interviewed. Mobility-related and behaviour disabilities were most prevalent. Disability rose with age and was higher among women, except for behaviour disabilities which were more frequent in young men. Mean handicap score was 78.0 +/- 12.7. Handicap dimensions most affected were physical independence and economic self-sufficiency. CONCLUSIONS: The health profile of the population hardest hit by TOS is characterized by the presence of important functional and psychosocial disabilities that limit performance of daily living activities and social role, and are in accord with the handicap that such persons suffer.


Assuntos
Pessoas com Deficiência/estatística & dados numéricos , Contaminação de Alimentos , Óleos de Plantas/intoxicação , Atividades Cotidianas , Adulto , Fatores Etários , Idoso , Brassica rapa , Estudos de Coortes , Transtornos da Comunicação/induzido quimicamente , Estudos Transversais , Avaliação da Deficiência , Feminino , Humanos , Masculino , Transtornos Mentais/induzido quimicamente , Pessoa de Meia-Idade , Doenças Neuromusculares/induzido quimicamente , Estudos de Amostragem , Fatores Sexuais , Espanha/epidemiologia , Inquéritos e Questionários
5.
No To Hattatsu ; 35(3): 259-63, 2003 May.
Artigo em Japonês | MEDLINE | ID: mdl-12755059

RESUMO

A case of forced normalization in childhood is presented. When zonisamide was administered to a five-year-old girl with intractable epilepsy, disappearance of seizures was accompanied by severe psychotic episodes such as communication disturbance, personal relationship failure, and stereotyped behavior, which continued after the withdrawal of zonisamide. These symptoms gradually improved by administration of fluvoxamine, however epileptic attacks reappeared. Although most patients with forced normalization are adult and teenager, attention should be paid to this phenomenon as adverse psychotic effects of zonisamide even in young children. Fluvoxamine may be effective for the symptoms.


Assuntos
Anticonvulsivantes/efeitos adversos , Transtornos do Comportamento Infantil/induzido quimicamente , Eletroencefalografia , Epilepsia/tratamento farmacológico , Isoxazóis/efeitos adversos , Psicoses Induzidas por Substâncias , Transtornos do Comportamento Infantil/tratamento farmacológico , Pré-Escolar , Transtornos da Comunicação/induzido quimicamente , Epilepsia/fisiopatologia , Feminino , Fluvoxamina/uso terapêutico , Humanos , Psicoses Induzidas por Substâncias/tratamento farmacológico , Zonisamida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA